Etoposide-related secondary acute myeloid leukemia (t-AML) in hemophagocytic lymphohistiocytosis

Pediatric Blood and Cancer

Volumn 48, Issue 2, 2007, Pages 121-123

  Imashuku, Shinsaku ^a  

^a Takasago seibu Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; CISPLATIN; CYCLOSPORIN A; DACTINOMYCIN; DEXAMETHASONE; DOXORUBICIN; EPIPODOPHYLLOTOXIN DERIVATIVE; ETOPOSIDE; GYRASE INHIBITOR; MIXED LINEAGE LEUKEMIA PROTEIN; TENIPOSIDE; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER RISK; CHILD; CHROMOSOME 11Q; CHROMOSOME ABERRATION; CLINICAL PROTOCOL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS; GENE MUTATION; GERM CELL TUMOR; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HISTIOCYTOSIS X; HUMAN; LEUKEMIA; LUNG NON SMALL CELL CANCER; LYMPHOMA; NOTE; PRIORITY JOURNAL; SECOND CANCER; SOLID TUMOR;

ACUTE DISEASE; ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; ETOPOSIDE; FEMALE; HUMANS; INFANT; LEUKEMIA, MYELOID; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MALE;

EID: 33845640169     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21082     Document Type: Note

References (20)

1. Pedersen-Bjergaard J, Philip P, Larsen SO, et al. Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series. Leukemia 1993;7:1975-1986.
2. Pui CH, Ribeiro RC, Hancock ML, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 1991;325:1682-1687.
3. Smith MA, Rubinstein L, Ungerleider RS. Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: Estimating the risks. Med Pediatr Oncol 1994;23: 86-98.
4. Ratain MJ, Kaminer LS, Bitran JD, et al. Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Blood 1987;70:1412-1417.
5. Le Deley MC, Vassal G, Taibi A, et al. High cumulative rate of secondary leukemia after continuous etoposide treatment for solid tumors in children and young adults. Pediatr Blood Cancer 2005; 45:25-31.
6. Janka GE, Schneider EM. Modern management of children with haemophagocytic lymphohistiocytosis. Br J Haematol 2004;124: 4-14.
7. Henter JI, Samuelsson-Horne A, Arico M, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood 2002;100:2367-2373.
8. Imashuku S, Kuriyama K, Teramura T, et al. Requirement for etoposide in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. J Clin Oncol 2001;19: 2665-2673.
9. Henter JI, Elinder G, Lubeck PO, et al. Myelodysplastic syndrome following epipodophyllotoxin therapy in familial hemophagocytic lymphohistiocytosis. Pediatr Hematol Oncol 1993;10:163-168.
10. Kitazawa J, Ito E, Arai K, et al. Secondary acute myelocytic leukemia after successful chemotherapy with etoposide for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Med Pediatr Oncol 2001;37:153-154.
11. Stine KC, Saylors RL, Sawyer JR, et al. Secondary acute myelogenous leukemia following safe exposure to etoposide. J Clin Oncol 1997;15:1583-1586.
12. Takahashi T, Yagasaki F, Endo K, et al. Therapy-related AML after successful chemotherapy with low dose etoposide for virus-associated hemophagocytic syndrome. Int J Hematol 1998;68: 333-336.
13. Ng A, Ravetto PF, Taylor GM, et al. Coexistence of treatment-related MLL cleavage and rearrangement in a child with haemophagocytic lymphohistiocytosis. Br J Cancer 2004;91:1990-1992.
14. Ohtake M, Suzuki R, Kondo S, et al. Etoposide-related t-AML in a case of EBV-HLH. Presented at the 16th Annual Meeting of EBV infection-related diseases, May 27, 2006; Tokyo (in Japanese).
15. Rudd E, Goransdotter Ericson K, Zheng C, et al. Spectrum and clinical implications of syntaxin 11 gene mutations in familial haemophagocytic lymphohistiocytosis: Association with disease-free remissions and haematopoietic malignancies. J Med Genet 2006;43:e14.
16. Imashuku S, Teramura T, Kuriyama K, et al. Risk of etoposide-related acute myeloid leukemia in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Int J Hematol 2002;75:174-177.
17. Teramura T, Tabata Y, Yagi T, et al. Quantitative analysis of cell-free Epstein-Barr virus genome copy number in patients with EBV-associated hemophagocytic lymphohistiocytosis. Leuk Lymphoma 2002;43:173-179.
18. Imashuku S, Kuriyama K, Sakai R, et al. Treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) in young adults: A report from the HLH study center. Med Pediatr Oncol 2003;41:103-109.
19. Stephan JL, Donadieu J, Ledeist F, et al. Treatment of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins, steroids, and cyclosporin A. Blood 1993;82:2319-2323.
20. Imashuku S, Tabata Y, Teramura T, et al. Treatment strategies for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH). Leuk Lymphoma 2000;39:37-49.